UNSPSC 51142434: Rizatriptan sulfate

This classification denotes a serotonin agonist 2C15H19N5.H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13RRH2218G, chemically known as 1h-indole-3-ethanamine, n,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-, sulfate (2:1), monohydrate, but more generally known as rizatriptan sulfate, which bears US NIH Compound Identifier 3038519. Most nations, for tariff and trade purposes, schedule rizatriptan sulfate under HS 29339990 and SITC 51577. As of Q4 2014, RIZATRIPTAN SULFATE remains US FDA's Preferred Term for this commodity.

Rizatriptan sulfate bears US NLM identifiers UMLS ID C1882957 and NCI Concept Code C66520. SMILES: CN(C)CCC1C[NH]C2C1CC(CC2)CN3CNCN3.CN(C)CCC1C[NH]C2C1CC(CC2)CN3CNCN3.O.OS(=O)(=O)O.

UNSPSC 51142434 Rizatriptan sulfate is a Commodity code that nominally names a specific migraine medication, but recent state and local solicitations tagged with this code reflect a much broader pharmaceutical procurement activity—generic pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems. The mismatch between the code's name and the actual scope of work being solicited suggests that state and local procurement offices are using this code as a catch-all for pharmaceutical and health-supply purchases rather than for rizatriptan specifically. Issuing bodies include state health and human services agencies, county health departments, and cooperative purchasing alliances serving multiple states. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a standout repeat buyer, soliciting manufacturers for generic multi-source pharmaceuticals and OTC products through a formal RFP process.

Recent activity spans multiple jurisdictions and procurement mechanisms. The Minnesota MMCAP issued an RFP on January 20, 2026 (due March 26, 2026) for generic pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota, Oregon, and other participating jurisdictions, with contract awards effective July 1, 2026 and pricing weighted 75 percent on competitiveness. The Texas Health and Human Services Commission posted a Request for Information on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to explore direct contracting models outside traditional pharmacy benefit managers. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, potentially funded through FEMA. These solicitations indicate active procurement of pharmaceutical products and health supplies across state agencies, county health departments, and cooperative purchasing vehicles, though the actual demand for rizatriptan specifically remains unclear from available records.